Oncolytic immunotherapy for metastatic cancer: lessons and future strategies.
作者信息
Guo Zong-Sheng
机构信息
UPMC Hillman Cancer Center and Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
出版信息
Ann Transl Med. 2020 Sep;8(17):1113. doi: 10.21037/atm.2020.04.42.
Abstract
摘要
相似文献
1
Oncolytic immunotherapy for metastatic cancer: lessons and future strategies.转移性癌症的溶瘤免疫疗法：经验教训与未来策略。
Ann Transl Med. 2020 Sep;8(17):1113. doi: 10.21037/atm.2020.04.42.
2
Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.抗肿瘤腺病毒免疫治疗药物的最新进展，用于治疗转移性癌症。
Cancer Gene Ther. 2013 Feb;20(2):70-6. doi: 10.1038/cgt.2012.95. Epub 2013 Jan 11.
3
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.溶瘤免疫疗法：释放病毒靶向治疗癌症的潜力。
Cancer Immunol Immunother. 2017 Oct;66(10):1249-1264. doi: 10.1007/s00262-017-2025-8. Epub 2017 Jul 15.
4
Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy.大数据为溶瘤病毒免疫疗法提供了新的见解。
Viruses. 2016 Feb 5;8(2):45. doi: 10.3390/v8020045.
5
Two roads for oncolytic immunotherapy development.肿瘤溶瘤免疫治疗的两条发展道路。
J Immunother Cancer. 2019 Feb 1;7(1):26. doi: 10.1186/s40425-019-0515-2.
6
Oncolytic Immunotherapy for Treatment of Cancer.溶瘤免疫疗法治疗癌症
Adv Exp Med Biol. 2016;909:241-83. doi: 10.1007/978-94-017-7555-7_5.
7
From virotherapy to oncolytic immunotherapy: where are we now?从病毒疗法到溶瘤免疫疗法：我们现在在哪里？
Curr Opin Virol. 2015 Aug;13:93-100. doi: 10.1016/j.coviro.2015.06.005. Epub 2015 Jun 26.
8
Intratumoral Immunotherapy-Update 2019.肿瘤内免疫治疗-2019 更新。
Oncologist. 2020 Mar;25(3):e423-e438. doi: 10.1634/theoncologist.2019-0438. Epub 2019 Nov 29.
9
Oncolytic Adenovirus: Prospects for Cancer Immunotherapy.溶瘤腺病毒：癌症免疫治疗的前景
Front Microbiol. 2021 Jul 21;12:707290. doi: 10.3389/fmicb.2021.707290. eCollection 2021.
10
The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.溶瘤病毒免疫疗法的限制因素及克服这些因素的方法。
Appl Microbiol Biotechnol. 2020 Oct;104(19):8231-8242. doi: 10.1007/s00253-020-10802-w. Epub 2020 Aug 20.
引用本文的文献
1
Development of attenuated Orf virus as a safe oncolytic viral vector for nasopharyngeal carcinoma treatment.减毒型羊口疮病毒作为安全的溶瘤病毒载体用于鼻咽癌治疗的研发。
Virol J. 2025 Feb 25;22(1):50. doi: 10.1186/s12985-025-02672-3.
2
Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.溶瘤病毒治疗中枢神经系统肿瘤的研究热点和趋势：文献计量学研究。
Front Immunol. 2022 Sep 6;13:975695. doi: 10.3389/fimmu.2022.975695. eCollection 2022.
3
Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations.用于肿瘤微环境治疗性编程的重组病毒载体：优势与局限
Biomedicines. 2022 Aug 31;10(9):2142. doi: 10.3390/biomedicines10092142.
4
The Viral Janus: Viruses as Aetiological Agents and Treatment Options in Colorectal Cancer.病毒两面性：病毒作为结直肠癌的致病因子及治疗选择
Front Cell Infect Microbiol. 2021 Jan 7;10:601573. doi: 10.3389/fcimb.2020.601573. eCollection 2020.
本文引用的文献
1
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study.一项关于塞内卡谷病毒（NTX-010）与安慰剂治疗广泛期小细胞肺癌（ES-SCLC）患者的随机双盲 II 期研究，这些患者在至少四个周期铂类化疗后病情稳定或有缓解：中北部癌症治疗组（Alliance）N0923 研究。
J Thorac Oncol. 2020 Jan;15(1):110-119. doi: 10.1016/j.jtho.2019.09.083. Epub 2019 Oct 9.
2
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.小细胞肺癌的免疫治疗：从分子前景到临床挑战。
J Immunother Cancer. 2019 Aug 5;7(1):205. doi: 10.1186/s40425-019-0690-1.
3
Optimizing oncolytic virotherapy in cancer treatment.优化溶瘤病毒治疗癌症。
Nat Rev Drug Discov. 2019 Sep;18(9):689-706. doi: 10.1038/s41573-019-0029-0. Epub 2019 Jul 10.
4
Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors.基于溶瘤病毒的细胞因子表达以改善脑肿瘤和实体瘤中的免疫活性
Mol Ther Oncolytics. 2019 Mar 20;13:14-21. doi: 10.1016/j.omto.2019.03.001. eCollection 2019 Jun 28.
5
Cold Tumors: A Therapeutic Challenge for Immunotherapy.冷肿瘤：免疫治疗的挑战。
Front Immunol. 2019 Feb 8;10:168. doi: 10.3389/fimmu.2019.00168. eCollection 2019.
6
The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer).2018年诺贝尔医学奖授予癌症免疫疗法（《BMC癌症》社论）。
BMC Cancer. 2018 Nov 12;18(1):1086. doi: 10.1186/s12885-018-5020-3.
7
Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2.利用表达重新设计的白细胞介素-2 的牛痘病毒来改变癌症免疫基准点。
Nat Commun. 2018 Nov 8;9(1):4682. doi: 10.1038/s41467-018-06954-z.
8
Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.超级激动剂 IL-15 武装溶瘤病毒引发强烈的抗肿瘤免疫和治疗作用，与 PD-1 阻断联合使用可增强疗效。
Mol Ther. 2018 Oct 3;26(10):2476-2486. doi: 10.1016/j.ymthe.2018.07.013. Epub 2018 Jul 17.
9
Integrating oncolytic viruses in combination cancer immunotherapy.将溶瘤病毒整合到联合癌症免疫疗法中。
Nat Rev Immunol. 2018 Aug;18(8):498-513. doi: 10.1038/s41577-018-0014-6.
10
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.肿瘤突变负荷与对PD-1抑制的反应率
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
Zotero 插件